BINAH CAPITAL GROUP INC
BCGNASDAQTrading Snapshot
- Day Range
- $1.05 – $1.09
- 52-Week Range
- $0.95 – $3.44
- Volume (shares)
- 4,430
- Avg Volume (shares)
- —
- Shares Outstanding
- 17.1M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $182M
- Last Q Revenue
- $47M
- P/E Ratio
- 4.4
- P/S Ratio
- 0.1x
- EPS (TTM)
- $0.25
- Dividend Yield
- 6.81%
- Dilution (1yr)
- +1.3%
BINAH CAPITAL GROUP INC
BCG
StockOtter · stockotter.spaceAbout BINAH CAPITAL GROUP INC
Binah Capital Group, Inc. (BCG), along with its associated companies, is active in the wealth management sector. The firm furnishes financial advisors with comprehensive execution capabilities for a broad spectrum of investments, including equities, fixed-income securities, exchange-traded funds (ETFs), and options. Furthermore, it supplies essential support services to these advisors, encompassing research, regulatory compliance, supervisory guidance, and accounting. BCG's product portfolio also features mutual funds and various insurance solutions, in addition to specialized alternative investments like non-traded real estate investment trusts (REITs), unit trusts, and both fixed and variable annuities. Established in 2016, Binah Capital Group maintains its corporate headquarters in Albany, New York, and operates as a subsidiary of MHC Securities, LLC.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for
Binah Capital Group, Inc. (NASDAQ:BCG) Stock Short Interest Report for September
Binah Capital Group, Inc. (NASDAQ: BCG - Get Free Report) was the recipient of a significant decline in short interest in September. As of September 30th, there was short interest totaling 2,413 shares, a decline of 61.0
Head-To-Head Comparison: Binah Capital Group (NASDAQ:BCG) versus Hennessy Advisors (NASDAQ:HNNA)
Binah Capital Group (NASDAQ: BCG - Get Free Report) and Hennessy Advisors (NASDAQ: HNNA - Get Free Report) are both small-cap finance companies, but which is the superior business? We will compare the two companies based